Stroke and Embolism Prevention in Atrial Fibrillation
This study is investigating two experimental medications, REGN7508 and REGN9933, for adults with atrial fibrillation (AF), a condition where the heart beats too fast and unevenly. This can lead to blood clots, increasing the risk of stroke. The study aims to see how safe and effective REGN7508 and REGN9933 are at preventing strokes or other blood clot events in people with AF who cannot or choose not to take standard blood thinners. To join, you must have AF and be at moderate to high risk for stroke. The study will measure how long it takes for a stroke or major bleeding event to occur, up to 36 months.
- Study design
- This interventional study plans to enroll 2628 participants. Participants will receive either REGN7508, REGN9933, or a placebo (an inactive substance).
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 36 months to track the occurrence of stroke, systemic embolism, or major bleeding.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
At a glance
Conditions
Where it's being run
18 sites across 9 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Time to first occurrence of ischemic stroke or systemic embolismUp to 36 months
- Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleedingUp to 36 months